Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Takeda UK Ltd to submit clinical- and cost-effectiveness evidence for brentuximab vedotin (BV) for treating relapsed or refractory CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL)....

Descripción completa

Detalles Bibliográficos
Autores principales: Stainthorpe, Angela, Fleeman, Nigel, Houten, Rachel, Chaplin, Marty, Boland, Angela, Beale, Sophie, Dundar, Yenal, McEntee, Joanne, Syndikus, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688836/
https://www.ncbi.nlm.nih.gov/pubmed/32207075
http://dx.doi.org/10.1007/s41669-020-00203-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688836/
https://www.ncbi.nlm.nih.gov/pubmed/32207075
http://dx.doi.org/10.1007/s41669-020-00203-0

Ejemplares similares